Trial reportBreast cancer research : BCR2014
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Trial report in Breast cancer research : BCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00002864 (A Randomized Trial of Antiestrogen Therapy Versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial of Antiestrogen Therapy Versus Combined Antiestrogen and Octreotide Therapy in the Adjuvant Treatment of Breast Cancer in Post-Menopausal Women
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis.Medicine · 2018Pooled it
- The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis.Scientific reports · 2015Pooled it
- Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.British journal of cancer · 2017Trial
- Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.Journal of translational medicine · 2017Trial
- Functional delineation of the luminal epithelial microenvironment in breast using cell-based screening in combinatorial microenvironments.Cellular signalling · 2024Article
- Sea buckthorn and its flavonoids isorhamnetin, quercetin, and kaempferol favorably influence bone and breast tissue health.Frontiers in pharmacology · 2024Review
- Immunohistochemical evaluation of osteopontin expression in triple-negative breast cancer.Archives of medical science : AMS · 2024Article
- Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.Oncology letters · 2021Article
- Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.Current oncology (Toronto, Ont.) · 2020Article
- Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.Scientific reports · 2020Article
- Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory BiomarkersFrontiers in oncology · 2019Article
- RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review.Hormones & cancer · 2018Review
- Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis.OncoTargets and therapy · 2018Review
- Current status of the prognostic molecular biomarkers in breast cancer: A systematic review.Oncology letters · 2017Article
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- Role of plasma osteopontin as a biomarker in locally advanced breast cancer.American journal of translational research · 2015Article
- Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review.Diagnostic pathology · 2014Review
- Far beyond the usual biomarkers in breast cancer: a review.Journal of Cancer · 2014Review
- Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteopontin (OPN) is a malignancy-associated glycoprotein that contributes functionally to tumor aggressiveness. In metastatic breast cancer, we previously demonstrated that elevated OPN in primary tumor and blood was associated with poor prognosis.
methodsWe measured OPN in plasma by ELISA, and in tumors by immunohistochemistry, in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide in a randomized trial (NCIC CTG MA.14; National Cancer Institute of Canada Clinical Trials Group Mammary.14).
resultsPlasma OPN was measured in 2,540 samples; 688 at baseline and 1,852 collected during follow-up. Mean baseline plasma OPN was 46 ng/ml (range 22.6 to 290) which did not differ from normal levels. Mean percentage OPN tumor cell positivity was 33.9 (95% CI: 30.2 to 37.9). There was no correlation between plasma and tumor OPN values. In multivariate analysis, neither was associated with event-free survival (EFS), relapse-free survival (RFS), overall survival (OS), bone RFS or non-bone RFS. An exploratory analysis in patients with recurrence showed higher mean OPN plasma levels 60.7 ng/ml (23.9 to 543) in the recurrence period compared with baseline levels.
conclusionsThe hypothesis that OPN tumor expression would have independent prognostic value in early breast cancer was not supported by multivariate analysis of this study population. Plasma OPN levels in women with hormone responsive early breast cancer in the MA.14 trial were not elevated and there was no evidence for prognostic value of plasma OPN in this defined group of patients. However, our finding of elevated mean OPN plasma level around the time of recurrence warrants further study.
trial registrationNCT00002864, http://clinicaltrials.gov/show/NCT00002864.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.